In the case of colorectal cancers (CRC), apart from KRAS and BRAF, which have been proven to be significant predictive markers of the anti-EGFR MoAb response [9], the PIK3CA exon-20 (H1047R) point mutation is likely to a potential predictive biomarker of personalized therapy for CRC [10, 11]. This evidence concerns the gene BRAF and colorectal carcinoma.